The Neuroscience iMed manages AstraZeneca’s entire portfolio of CNS and pain programs from target identification through Phase II proof of concept studies. The iMed (short for Innovative Medicines) is built around a bold collaborative approach that brings together the great science of the biotech and academic worlds with the scientific and commercial reach of AstraZeneca, one of the world’s largest global biopharmaceutical companies. With a high energy team of R&D experts and culture and energy much like a small biotech, the iMed operates out of neuroscience hubs in Cambridge, Massachusetts, US, and in Cambridge, UK.
If you are interested in working with the AstraZeneca Neuroscience iMed team, please contact us:
Potential scientific collaborators:
Potential post-doctoral candidates: